Scott Gottlieb Calls It Quits After An Active Tenure At US FDA
Executive Summary
The commissioner says he will step down next month, leaving a legacy of active policy development, but also a lot of initiatives and pilot projects that are in the middle of being implemented.
You may also be interested in...
Contrary To Trump, Gottlieb Says The US Had ‘Late Start’ Testing For COVID-19
Despite the White House’s insistence it has been quick and decisive in its response to the COVID-19 crisis, former FDA commissioner Scott Gottlieb – who has been advising the administration – said on 6 May that the government should’ve responded months sooner to ensure there was enough testing.
Trump Nominates Hahn As New FDA Commish; Acting Head Sharpless Returns To NCI
The White House has announced President Trump’s intent to nominate MD Anderson’s Stephen Hahn as the next FDA commissioner. The position has been held by acting commissioner Ned Sharpless for the past seven months. Admiral Brett Giroir will helm the agency on an acting basis until the new commissioner is confirmed.
MTI Profile: US FDA's Second-In-Command Has Her Eye On A Tech-Forward Future
As principal deputy commissioner of the FDA, Amy Abernethy is focused on developing overarching policies that affect all its product centers. But perhaps what will stand as her legacy is her work to develop a data-centered strategy to improve how the agency reviews products and ensures their long-term safety and efficacy.